Center for Rehabilitation Medicine, Department of Anesthesiology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, People's Republic of China.
Department of Anesthesiology, Lishui People's Hospital, Wenzhou Medical University Lishui Hospital, Lishui, People's Republic of China.
Drug Des Devel Ther. 2024 Sep 4;18:3951-3958. doi: 10.2147/DDDT.S475176. eCollection 2024.
Ciprofol is a new intravenous sedative / anesthetic drug. In recent years, many clinical studies have also confirmed the sedative effect of ciprofol. However, more clinical research is still needed on its clinical application characteristics in special populations.
The aim of this study was to compare the clinical effects of ciprofol and propofol in general anesthesia induction of elderly patients.
60 elderly (aged ≥ 75 years) patients underwent hip fracture surgery were randomly into two groups of a 1:1 ratio. Group C (ciprofol group): 0.3mg/kg ciprofol was infused. Group P (propofol group): 1.5mg/kg propofol was infused. The observation period was from the infusion of test drug to 5 min after endotracheal intubation. The primary outcomes included the incidence of severe hypotension and hypotension during the observation period. The secondary outcomes were as follows: the success rate of general anesthesia induction, the number of additional sedation, the time of loss of consciousness (LOC), Δ MAP, Δ HR, adverse events and the frequency of vasoactive drugs used.
Finally, 60 subjects completed the study. Compared with Group P, the incidence of severe hypotension in Group C was lower (26.7% vs 53.3%, = 0.035), the incidence of hypotension was also lower (36.7% vs 63.3%, = 0.037), Δ MAP in Group C was significantly lower (31.4 ± 11.4 vs 39.6 ± 15.7, = 0.025), the frequency of ephedrine used and the incidence of injection pain in Group C were also significantly lower.
Ciprofol showed similar efficacy to propofol when used for general anesthesia induction in elderly patients underwent hip fracture surgery and could maintain more stable blood pressure.
西普罗夫是一种新型的静脉镇静/麻醉药物。近年来，许多临床研究也证实了西普罗夫的镇静作用。然而，对于其在特殊人群中的临床应用特点，还需要更多的临床研究。
本研究旨在比较西普罗夫与丙泊酚在老年患者全身麻醉诱导中的临床效果。
选择行髋关节骨折手术的老年（年龄≥75 岁）患者 60 例，采用 1∶1 随机分组，分为西普罗夫组（C 组）和丙泊酚组（P 组）。C 组：静脉注射 0.3mg/kg 西普罗夫；P 组：静脉注射 1.5mg/kg 丙泊酚。观察期为从试验药物输注至气管插管后 5min。主要结局指标包括观察期内严重低血压和低血压的发生率。次要结局指标包括：全身麻醉诱导成功率、追加镇静药物例数、意识消失时间（LOC）、MAP 变化值（ΔMAP）、心率变化值（ΔHR）、不良反应以及血管活性药物使用频率。
最终 60 例患者完成研究。与 P 组比较，C 组严重低血压发生率较低（26.7%比 53.3%， = 0.035），低血压发生率也较低（36.7%比 63.3%， = 0.037），C 组 MAP 变化值较低（31.4±11.4 比 39.6±15.7， = 0.025），麻黄碱使用率和注射痛发生率也较低。
西普罗夫用于髋关节骨折手术老年患者全身麻醉诱导时，与丙泊酚具有相似的效果，可维持更稳定的血压。
